Henry Schein, Inc. HSIC is primed for growth in the upcoming quarters due to its expansion efforts through acquisitions and partnerships. The company’s innovative offerings in the growing global dental market also hold significant potential for long-term success. Also, its strategic placement of distribution centers worldwide gives a competitive edge in the industry. Meanwhile, macroeconomic challenges and a tough competitive landscape remain concerns for the company. In the past year, this Zacks Rank #3 (Hold) stock has fallen 20.7% compared with the 3.9% decline of the industry and the 24.9% rise of the S&P 500 composite. The leading distributor of healthcare products and services has a market capitalization of $8.22 billion. Henry Schein surpassed estimates in two of the trailing four quarters, broke even in one quarter and missed in one, delivering an average earnings surprise of 2.55%. Let’s delve deeper. Tailwinds Bolstering Growth Through Strategic Moves: Henry Schein’s robust acquisition strategy helps it pursue targets that provide access to additional product lines. In late December, the company entered into the extremity segment of the growing orthopedic market through an agreement to acquire a majority interest in TriMed and a strategic relationship with Extremity Medical. The addition of Shield Healthcare expands the company’s existing medical business with products like incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes supplies. Furthermore, Henry Schein acquired a majority share in Biotech Dental, which increased the prospect of offering a seamless digital workflow solution. The company also signed a definitive agreement to acquire S.I.N. Implant System, one of Brazil’s leading manufacturers of dental implants. The announcement marks Henry Schein’s planned entry into Brazil’s large implant market. Its broad global footprint has evolved, supported by the contributions of these strategic acquisitions. Zacks Investment Research Image Source: Zacks Investment Research Dental Business Trends Support Long-Term Prospects: The $433.2 billion valued (as of 2022) global dental service market is expected to grow steadily in the next few years. Amid this, Henry Schein’s efforts to expand digital dentistry globally are encouraging. The company has its own cost-effective consumable merchandise products and manufactures certain dental specialty products in the areas of implants, orthodontics and endodontics. Of late, the company is witnessing consistent demand for these implant systems and endodontic products and integrated software and services solutions. Further, Henry Schein is organically gaining shares in the Global Dental specialties market, with acquisitions leading to significant growth across oral surgical, endodontics and orthodontics product lines. Throughout the first quarter, dental merchandise sales made steady improvement, while international merchandise sales also experienced a similar trend in most markets. The newly launched Easy 2.0 value implant system in Germany supported international sales growth. Widespread Network and Channel Mix: Henry Schein has set up distribution centers worldwide to better serve customers and increase its operating efficiency. Apart from North America, the company’s presence spans Australia and New Zealand, as well as emerging nations like China, Brazil, Israel, the Czech Republic and Poland. The growth in the healthcare distribution industry is a positive sign for the business, indicating a growing awareness of the benefits of preventative care and oral hygiene. We believe Henry Schein’s worldwide reach is a major competitive advantage over other players in the industry. Following last year's cyber incident, the dental and medical distribution businesses in North America and Europe have bounced back well. In the first quarter of 2024, the company’s Technology and Value-Added service sales grew 13.8% from the prior-year quarter’s levels. Sales growth in North America was primarily driven by value-added services, while international growth was driven by the Dental cloud-based solution. Downsides Macroeconomic Challenges: The global macroeconomic environment, including exchange rate fluctuations, inflation and recession, is affecting Henry Schein’s financial operations. Amid efforts by the governments and insurance companies to contain the rising healthcare costs, the company may struggle to keep in check its cost of revenues and operating expenses under these persistent macro challenges. In the first quarter, Henry Schein’s selling, general & administrative expenses rose 10.3% from the comparable 2023 figure. Competitive Space: The U.S. healthcare products and service distribution industry is highly competitive and consists principally of national, regional and local distributors. In the North American dental products market, the company faces stiff competition from the Patterson Dental business of Patterson Companies Inc. and Benco Dental Supply. Henry Schein operates in a highly competitive medical product distribution market with larger players like McKesson Corp. The competitive landscape in the overseas market is also tough. The tussle for market share might be a drag on results. Estimate Trend The Zacks Consensus Estimate for HSIC’s 2024 earnings per share (EPS) has moved south 0.2% to $5.16 in the past 30 days. The Zacks Consensus Estimate for the company’s 2024 revenues is pegged at $13.34 billion. This suggests an 8.1% rise from the year-ago reported number. Key Picks Some better-ranked stocks in the broader medical space are Hims & Hers Health HIMS, Haemonetics HAE and Medpace MEDP Hims & Hers Health’s earnings are expected to surge 281.8% in 2024 compared with the industry’s 15.7% growth. HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. Its shares have surged 131% against the industry’s 27.1% decline in the past year. HIMS sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Haemonetics, sporting a Zacks Rank #1 at present, has an estimated fiscal 2025 earnings growth rate of 15.4% compared with the industry’s 12.8%. Shares of HAE have dropped 45.3% against the industry’s 0.6% growth over the past year. HAE’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 13.2%. In the last reported quarter, it delivered an earnings surprise of 2.3%. Medpace, carrying a Zacks Rank #2 (Buy) at present, has an estimated 2024 earnings growth rate of 27.1% compared with the industry’s 13.1%. Shares of MEDP have rallied 80.9% compared with the industry’s 5.2% growth over the past year. MEDP’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Henry Schein, Inc. (HSIC):Free Stock Analysis Report Haemonetics Corporation (HAE):Free Stock Analysis Report Medpace Holdings, Inc. (MEDP):Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...